Patients with SSc experience increased levels of endothelin-1 due to endothelial cell injury [162], so ERAs have been suggested as a possible treatment for SSc vascular manifestations including digital ulcers and PAH. The gene discussed is EDN1; the disease is pulmonary arterial hypertension.